Skip to content

OS Therapies OSTX Operating Cash Flow

Operating Cash Flow at other companies

Immunome logo
ImmunomeIMNM
-$58.64M-10.5%
CTO
Citius Oncology, Inc.CTOR
-$3.83M-179%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$17.69M-87.1%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$75.36M+12.3%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$138M-4.5%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
CapEx$316.4K
Free cash flow-$3.7M

Valuation

See full
Market cap$84.62M+66.4%
Enterprise value$103.7M

Returns & leverage

See full
Return on equity470%
Debt / equity-1.8×
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's operating cash flow?
OS Therapies (OSTX) reported operating cash flow of -$4.56M in Q1 2026.
How has OS Therapies's operating cash flow changed year-over-year?
OS Therapies's operating cash flow decreased by 32.6% year-over-year, from -$3.44M to -$4.56M.
What is the long-term trend for OS Therapies's operating cash flow?
Over 2 years (2023 to 2025), OS Therapies's operating cash flow has grown at a 117.6% compound annual growth rate (CAGR), from -$3.01M to -$14.24M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.